Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge

BACKGROUND: The introduction of the immunomodulatory drug lenalidomide has revolutionized the treatment of patients with myelodysplastic syndromes (MDS) and deletion of the long arm of chromosome 5. Treatment with lenalidomide results in transfusion independence in the majority of patients, but some...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisani, Francesco, Orlandi, Giulia, Merola, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: April, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036206/
https://www.ncbi.nlm.nih.gov/pubmed/24926257
http://dx.doi.org/10.1159/000362643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036206/
https://www.ncbi.nlm.nih.gov/pubmed/24926257
http://dx.doi.org/10.1159/000362643

Ejemplares similares